Abstract
Psoriasis has been for a long time a distressing skin disease difficult to treat. Several topical and systemic drugs have been used successfully in the treatment but the most active drugs are also the most difficult to manage in a long term treatment. Discovering the pathogenesis of this skin disorder has suggested that anti tumor necrosis factors agents could be an alternative treatment. Up to now several manuscripts show data supporting the idea that anti TNF are safe and effective more than other drugs. On the experience of dermatologists using this drug in a large number of patients TNF inhibitors are very effective drugs with a relatively safe management. At the moment several drug companies are developing a second generation of biologic drugs with different targets. This review point out the actual knowledge about anti TNF drugs and their activities on psoriasis both clinically and biologically.
Keywords: Psoriasis, therapy, anti TNF, biological agents, tumor necrosis factor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Volume: 8 Issue: 1
Author(s): D. Digiuseppe and C. Feliciani
Affiliation:
Keywords: Psoriasis, therapy, anti TNF, biological agents, tumor necrosis factor
Abstract: Psoriasis has been for a long time a distressing skin disease difficult to treat. Several topical and systemic drugs have been used successfully in the treatment but the most active drugs are also the most difficult to manage in a long term treatment. Discovering the pathogenesis of this skin disorder has suggested that anti tumor necrosis factors agents could be an alternative treatment. Up to now several manuscripts show data supporting the idea that anti TNF are safe and effective more than other drugs. On the experience of dermatologists using this drug in a large number of patients TNF inhibitors are very effective drugs with a relatively safe management. At the moment several drug companies are developing a second generation of biologic drugs with different targets. This review point out the actual knowledge about anti TNF drugs and their activities on psoriasis both clinically and biologically.
Export Options
About this article
Cite this article as:
Digiuseppe D. and Feliciani C., Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (1) . https://dx.doi.org/10.2174/187152309787580766
DOI https://dx.doi.org/10.2174/187152309787580766 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Synthesis, Molecular Docking and In Vitro Antimicrobial Studies of New Hexahydroindazole Derivatives of Curcumin
Letters in Drug Design & Discovery Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Identification of Antibacterial Molecule(s) from Animals Living in Polluted Environments
Current Pharmaceutical Biotechnology Commentary (Research Highlights: Transcranial Drug Delivery for Neurological Disorders)
CNS & Neurological Disorders - Drug Targets Design and Optimization of Itraconazole Loaded SLN for Intranasal Administration Using Central Composite Design
Nanoscience & Nanotechnology-Asia Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design The Possible Role of Pathogenic and Non-Pathogenic Bacteria in Initiation and Exacerbation of Celiac Disease; A Comprehensive Review
Current Pharmaceutical Biotechnology Liposomes as Potential Carrier System for Targeted Delivery of Polyene Antibiotics
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
Current Pharmaceutical Biotechnology Editorial [ Hot Topic:Stroke Bugs: Current and Emerging Concepts Relevant to Infection in Cerebrovascular Disease (Guest Editors: Hedley CA Emsley and Angel Chamorro)]
Infectious Disorders - Drug Targets Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study
Current HIV Research Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Cisternal Sustained Release Dihydropyridines for Subarachnoid Hemorrhage
Current Neurovascular Research Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine